Methicillin

Summary

Methicillin (CHEMBL575) is an approved small-molecule antibacterial drug (ATC J01CF03); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CF03
• Indications: 2 conditions
• Chemistry: 380.4 Da · C17H20N2O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL575
Name	Methicillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6087
ChEBI	CHEBI:6827
ATC	J01CF03
Molecular formula	C17H20N2O6S
Molecular weight	380.4
InChIKey	RJQXTJLFIWVMTO-TYNCELHUSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Methicillin, Meticilina, Meticillin, Meticilline, methicillin, METICILLINE, METHICILLIN, METICILLIN, meticillin, Methiciilin

Parent form; salt/anhydrous children: CHEMBL1164, CHEMBL3181832

Patent coverage: 18,136 distinct patent families (53,442 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 1, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE3A	5.55	AC50	2808	nM	CHEMBL_ACT_25192097

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).